SWI/SNF-Compromised Cancers Are Susceptible to Bromodomain Inhibitors

Tatiana Shorstova1, Maud Marques1, Jie Su1

  • 1Departments of Oncology and Experimental Medicine, McGill University, Lady Davis Institute and Segal Cancer Centre, Jewish General Hospital, Montreal, Quebec, Canada.

Cancer Research
|March 17, 2019
PubMed

Insights

Loss of SMARCA4/A2 predicts sensitivity to bromodomain and extraterminal motif protein inhibitors (BETi) in aggressive ovarian and lung cancers. These findings identify potential biomarkers for BET inhibitor therapy.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Therapeutics

Background:

  • Bromodomain and extraterminal motif protein inhibitors (BETi) show antitumor activity but lack predictive biomarkers for patient stratification.
  • SWI/SNF chromatin remodeling complexes, including SMARCA4 and SMARCA2, are crucial in cancer development.

Purpose of the Study:

  • To investigate the therapeutic potential of BET inhibitors in aggressive cancers lacking SMARCA4 and SMARCA2.
  • To identify predictive biomarkers for response to BET inhibitors.

Main Methods:

  • In vitro and in vivo antiproliferative assays using ovarian and lung cancer models.
  • Genetic manipulation (restoration and knockdown) of SMARCA4 and SMARCA2.
  • Transcriptomic analysis to identify molecular pathways affected by BET inhibitors.

Main Results:

  • Low-dose BET inhibitors demonstrated significant antiproliferative effects in SMARCA4/A2-deficient cancer models.
  • Restoration of SMARCA4/A2 conferred resistance to BET inhibitors, while knockdown sensitized resistant cells.
  • BET inhibitors downregulated receptor tyrosine kinase (RTK) signaling, including HER3, in deficient cells, which determined response.

Conclusions:

  • Loss of SMARCA4/A2 identifies tumors hypersensitive to BET inhibitors.
  • BET inhibitors represent a rational therapeutic strategy for poor-prognosis SMARCA4/A2-deficient cancers.
  • SMARCA4/A2 deficiency serves as a predictive biomarker for BET inhibitor efficacy.

Related Concept Videos

Eukaryotic Transcription Inhibitors01:52

Eukaryotic Transcription Inhibitors

Certain biochemical processes, such as embryonic development and cell growth regulation, depend on the repression of specific genes. DNA binding proteins known as eukaryotic transcription inhibitors regulate the repression of gene expression in eukaryotes. The presence of these inhibitors at the required location and time in the cell is triggered by the presence of hormones and additional signals from other cells.
Eukaryotic transcription inhibitors usually contain two distinct domains, a...
11.0K
Magnetic Susceptibility and Permeability01:31

Magnetic Susceptibility and Permeability

In linear magnetic materials, like paramagnets and diamagnets, magnetization is proportional to the magnetic field intensity. The constant of proportionality, a dimensionless number, is called magnetic susceptibility. The value of the susceptibility depends on the type of material.
When diamagnetic materials are placed under an external magnetic field, the moments opposite to the field are induced. Hence, the susceptibility for diamagnets has a minimal negative value of 10-5–10-6. Since...
2.4K
Susceptibility, Permittivity and Dielectric Constant01:26

Susceptibility, Permittivity and Dielectric Constant

When placed in an external electric field, a dielectric material gets polarized. The charge density in the dielectric material is given by the sum of the bound and free charge densities, while the total charge density can also be written in terms of the total electric field. The bound charge density can be measured in terms of polarization, leading to the relationship between electric displacement and polarization.
2.8K
Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
643
Antihypertensive Drugs: Direct Renin Inhibitors01:25

Antihypertensive Drugs: Direct Renin Inhibitors

The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
1.5K
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors01:30

Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors

Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
2.5K